202 Incremental costs1 Incremental QALYs1 ICER2 Base case3 -28,616 0.37 CS Other scenarios Time horizon 5 years -14,670 0.07 CS 10 years -26,042 0.20 CS Starting sample distribution 100% CKD 1/2 -18,188 0.44 CS 100% CKD 3/4 -29,437 0.37 CS Starting age 55 years old4 -45,509 0.81 CS Mortality risk Constant for all stages5 -75,102 0.17 CS Extra costs Indirect medical costs -25,682 0.37 CS Work hours lost by professionals -28,611 0.37 CS Intervention effect Only in the first year 19,5891 0.74 26,530 Constant over time -37,112 0.48 CS No effect on transition to CKD 3/4 -28,081 0.35 CS No effect on transition to ESRD 683 0.02 31,116 Non-discounted costs and QALYs -35,718 0.43 CS QALY: Quality-adjusted life year; ICER: Incremental cost-effectiveness ratio (in euros/QALY); CS: cost-saving; CKD 1/2: Chronic kidney disease stages 1 or 2; CKD 3/4: Chronic kidney disease stages 3 or 4 1 Costs and QALYs per patient over the lifetime, unless otherwise defined 2 Considering a willingness-to-pay threshold of €80,000/QALY gained 3 Parameters of base case: lifetime horizon, percentage of sample starting in CKD 1/2 = 7.3%, starting age = 70 years, indirect medical costs and work hours lost by professionals not included, intervention effect decreases by 12.5% every year, costs and QALYs discounted at annual rates of 4% and 1.5%, respectively 4 Percentage of sample starting in CKD 1/2 = 59.3% 5 Equal to Dutch age-dependent all-cause mortality Table 6.2 Scenario analyses
RkJQdWJsaXNoZXIy MTk4NDMw